|Date||Title|| || |
|2/7/2019||Meridian Launches New Range of Lyo-Ready PCR Mixes|
|CINCINNATI, Feb. 07, 2019 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced that following the successful release of the Lyo-Ready qPCR Mix, Meridian is proud to introduce its next-generation lyophilization-ready mixes for one-step RT-qPCR. These master mixes offer new solutions for developing freeze-dried multiplex assays that can simultaneously detect both RNA and DNA viruses.
Lyo-Ready One-Step RT-qPCR and Lyo-Ready One-Step Viral RT-qPCR are glycerol-free for... || |
|1/24/2019||Meridian Bioscience Reports First Quarter 2019 Operating Results, Declares Regular First Quarter Cash Dividend, and Provides Updated Fiscal 2019 Guidance|
|CINCINNATI, Jan. 24, 2019 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the first quarter ended December 31, 2018.
First Quarter 2019 Highlights:
Total revenue decreased 1.5% to $51.5 million, as compared to $52.3 million in the first quarter of fiscal 2018 (1% decrease in constant-currency)
Reported operating income of $10.6 million (including $0.6 million of costs associated with litigation), an increase of 31% from the first qu... || |
|1/7/2019||Meridian Bioscience Announces Preliminary First Quarter 2019 Revenue; First Quarter 2019 Financial Results Conference Call to be Held on January 24, 2019|
|CINCINNATI, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, announced that it expects first quarter 2019 revenue to be approximately $51.0 million to $51.5 million compared to $52.3 million in the first quarter of 2018. The year-over-year decline of approximately 2% is being driven by weakness in the Diagnostics segment. The Life Science segment is expected to post revenue about in line wit... || |